Report of Foreign Issuer (6-k)
May 12 2020 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 11, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares
by board members, executives and associated persons on 11 May 2020
Bagsværd, Denmark, 11 May 2020 — This document
discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s
board members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
1
|
Details of the person discharging managerial responsibilities/person
closely associated
|
a)
|
Name of
the Board member/Executive/Associated Person
|
Novo Holdings
A/S Associated to Kasim Kutay
|
2
|
Reason
for the notification
|
a)
|
Position/status
|
Member of the Board
of Directors
|
b)
|
Initial notification/Amendment
|
Initial notification
|
3
|
Details
of the issuer
|
a)
|
Name
|
Novo Nordisk A/S
|
b)
|
LEI
|
549300DAQ1CVT6CXN342
|
4
|
Details
of the transaction(s)
|
a)
|
Description of the financial instrument, type of instrument,
Identification code
|
Shares
Novo Nordisk B DK0060534915
|
b)
|
Nature of the transaction
|
Sale of shares
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 32 / 2020
|
Page 2 of 3
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
435.05
|
7,012,500
shares
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
7,012,500 shares
435.05
|
e)
|
Date of the transaction
|
2020-05-11
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
Definitions and background information:
Publication
Publication shall take place no later than three working days
after the trading by board members, executives or their associated persons. Publication is only required when the total amount
of transactions of a specific board member/executive or his/her associated persons in any one calendar year has reached EUR 20,000
(calculated individually).
Who are board members, executives and associated
persons?
Board members and executives are members of the Board of Directors
and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated
to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined as brothers,
sisters, parents, grandparents, children, grandchildren, cousins etc. who have shared the same household with a board member or
executive for a period of at least one year on the date of the given transaction and 4) any legal persons, trust, or partnership,
the managerial responsibilities of which are discharged by a board member/executive or by a person referred to in items 1)-3)
above, or which is directly or indirectly controlled by such a person, or which is set up for the benefit of such a person, or
the economic interests of which are substantially equivalent to those of such a person.
What is trading/transaction?
Trading is any kind of transaction, including shares and share
related securities purchased or otherwise acquired, sold or otherwise disposed, gifts, mortgages, heritage and grants, allotments
and exercise of options.
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 32 / 2020
|
Page 3 of 3
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq Copenhagen
and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code
is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place
of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock Exchange.
What is the volume and price of transaction
and aggregated information?
The volume of transaction is the number of shares (of DKK 0.20
nominal value) or other financial instruments traded. In case of a single transaction the price is the price of that single transaction.
In case of multiple transactions, when the transactions relate to the same financial instrument, are of the same nature, are executed
on the same day and are executed on the same place, the volume must be aggregated. The price of the aggregated transactions is
the weighted average price.
The exchange rate of the Danish Central Bank (Nationalbanken)
on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such
as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines
and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products
in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 4442 3883
|
mkd@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 32 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 11, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Aug 2023 to Aug 2024